Lazarová Z, Edelsteinová S, Lojda Z
Department of Pharmacodynamics and Toxicology, Pharmaceutical Faculty, Bratislava, Czechoslovakia.
Cor Vasa. 1991;33(6):480-91.
The aim of the study was to assess the dose dependence of the antiatherogenic effect of verapamil (Isoptin, Lek Ljubljana, Yugoslavia) in rabbits fed 1% cholesterol diet. Verapamil was administered subcutaneously at doses of 0.25, 1 and 2 mg.kg-1/day at 12-hour intervals for 8 weeks. The results indicate verapamil administered s.c. exerts a preventive anti-atherosclerotic effect only in therapeutic doses (0.25 mg.kg-1). The beneficial effect of low-dose verapamil can also be seen in the spectrum of serum lipids as the drug lowers the levels of total cholesterol and triacylglycerols. Compared with the results obtained from a group receiving diet without Ca-antagonist premedication, high doses do not reduce the extent of atheromatous plaques.
本研究的目的是评估维拉帕米（异搏定，南斯拉夫卢布尔雅那莱克制药厂生产）对喂食1%胆固醇饮食的家兔抗动脉粥样硬化作用的剂量依赖性。维拉帕米以0.25、1和2毫克·千克⁻¹/天的剂量皮下注射，每12小时一次，持续8周。结果表明，皮下注射维拉帕米仅在治疗剂量（0.25毫克·千克⁻¹）时发挥预防性抗动脉粥样硬化作用。低剂量维拉帕米的有益作用还体现在血脂谱方面，因为该药物可降低总胆固醇和三酰甘油水平。与未预先使用钙拮抗剂进行饮食治疗的组所获得的结果相比，高剂量并不能减少动脉粥样斑块的范围。
